Focus on Managed Care Pharmacy

(EDU-M5) AMCP Partner Session: The Evolving U.S. Biosimilars Landscape: A Look into the Future

Thursday, October 13, 2022

2:45 PM – 4:00 PM ET

Location: Potomac C

ACPE UAN:N/A | Contact Hours: N/A | Activity Type: N/A

Faculty(s)

Jeremy Fredell, PharmD, BPS

Managing Director Drug Strategy & Business Development
Express Scripts
Warrendale, PA
Chelsee Jensen, PharmD

Pharmaceutical Formulary Manager
Mayo Clinic
Rochester, MN
Eugene Rozenblyum, PharmD

Director, Trade Relations & Enterprise Drug Solutions
Excellus BCBS
Rochester, NY

Moderator(s)

Billy West, PharmD, MBA

Executive Director/General Manager, National Accounts
Amgen
Brentwood, TN

This session is sponsored by Amgen and is not accredited for continuing pharmacy education contact hours.

Since the first biosimilar launched in the U.S. in 2015, the number of approved biosimilars has continued to accelerate in the United States. Competition driven by biosimilars has improved patient access to critical medications and helped to foster a resilient U.S. healthcare system, all while contributing to decreased drug spending. Looking ahead, how can stakeholders promote a competitive landscape that continues to encourage biosimilar uptake? What considerations should payers, providers and pharmacists keep in mind as biosimilars expand into new therapeutic areas?

This session will focus on the evolving U.S. biosimilars marketplace and how stakeholders can adopt and implement biosimilars within their organizations. Leveraging Amgen’s 2022 Biosimilar Trends Report and an expert industry panel, we will discuss key trends in the U.S. biosimilars marketplace and its impact across a variety of industry segments.

Learning Objectives:

At the completion of this activity, participants should be able to:

Present key trends from the 2022 Amgen Biosimilar Trends Report reflecting the current U.S. biosimilars marketplace.
Discuss how the broader healthcare landscape may shift as biosimilars expand into new therapeutic areas.
Share how various stakeholders play a role in facilitating biosimilar adoption and implementation .